Profil opens first U.S. clinical research unit in Texas

By AI, Created 11:08 AM UTC, May 20, 2026, /AGP/ – Profil is expanding its metabolic drug development footprint into the U.S. through a merger with Tranquil Clinical Research and Consulting Services in Houston (Webster), Texas. The move gives the German CRO its first U.S. clinical research unit and adds capacity for faster recruitment, broader participant access and more flexible early-phase trials.

Why it matters: - Profil’s U.S. expansion gives the metabolic CRO a second early-phase clinical research hub and a larger footprint for global drug development programs. - The Houston-area site adds 30+ beds and access to a diverse participant pool, which can speed recruitment for complex metabolic trials. - The move is designed to bring Profil’s specialized research methods, including automated glucose clamp technology, closer to global partners.

What happened: - Profil announced the expansion of its clinical operations to Houston (Webster), Texas through a merger with Tranquil Clinical Research and Consulting Services, LLC. - The transaction creates Profil’s first U.S. clinical research unit. - Karim Mohammed, owner of Tranquil, will become a significant minority shareholder of Profil under the merger agreement. - The new structure places Tranquil as a subsidiary of Profil USA, Inc., with Karim Mohammed leading Profil USA, Inc. as CEO. - Profil said the transfer of its specialized metabolic research methodologies is already underway and will be completed over the coming months.

The details: - Tranquil was founded in 2013 and has built a reputation as a CRO/CRU partner for the pharmaceutical industry. - Tranquil has been selected by the FDA to conduct FDA-sponsored trials since late 2025. - The Houston metropolitan location is intended to support rapid recruitment from a large and diverse participant population. - Profil said the expansion should improve start-up timelines and operational flexibility while maintaining its quality standards. - Profil was founded in 1999, is headquartered in Neuss, Germany, and now operates two early-phase clinical research units in Germany and the U.S. with 100+ beds total. - Profil provides full-service clinical development support, including trial consultation, regulatory submission, trial execution, biometrics and medical writing. - After the merger, the parent company will be Profil Institute Holding GmbH, with two subsidiaries: Profil Institut für Stoffwechselforschung GmbH and Profil USA, Inc. - Prof. Dr. Leona Plum-Mörschel will continue leading Profil Institut für Stoffwechselforschung GmbH and Profil Institute Holding GmbH. - Karim Mohammed will lead Profil USA, Inc., and Tranquil will continue CRO services within that subsidiary.

Between the lines: - The expansion appears aimed at shortening timelines in a trial segment where patient access and specialized methodology can be major bottlenecks. - Profil is also signaling that it wants to localize more of its metabolic research workflow inside the U.S. rather than serving the market only from Europe. - The merger combines Profil’s established metabolic expertise with a U.S. site that already has clinical trial infrastructure and FDA-sponsored trial experience.

What’s next: - Profil said the technology transfer for its metabolic research methods will continue over the coming months. - The company expects the Houston unit to support faster study start-up and more flexible trial operations as the integration progresses. - Profil said the U.S. expansion is part of its continued international development.

The bottom line: - Profil is turning a merger into a strategic U.S. beachhead for metabolic trials, with more bed capacity, broader recruitment reach and closer access for global sponsors.